What is PROF's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PROF.

Stock Ratings / Health Care / PROF / options

UTMD (62) OSUR (31) INFU (77) ANIK (53) ⌘ Pro Terminal →

Profound Medical Corp. (PROF) Options Positioning, Max Pain & Unusual Sweeps

$6.73 +2.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.75

Profound Medical Corp. (PROF) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $240.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PROF Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PROF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Profound Medical Corp. (NASDAQ: PROF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $6.73 (+2.44% 1D, market cap $240.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PROF ranks #463 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PROF compare to UTMD and OSUR in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), PROF carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 70.8%, and ROIC of -35.0%. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and OSUR (OraSure Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $271.7M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PROF?

▼

Per PROF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628808), Profound Medical Corp. generated $16.1M in revenue (+65.3% YoY), -$42.6M in net income, and -$38.4M in free cash flow against $77.5M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.75 (+0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PROF)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY PROF SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (35% of score)

Altman Z-Score 5.97 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$7.01-15.5% Next Q

Q2 (-2Q)

Grade D$5.92-4.7% Next Q

Q3 (-1Q)

Grade D$5.64+19.3% Next Q

Current

Grade D-$6.73-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PROF Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PROF currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.20) and Max Pain ($7.07) forces dealer call-delta covering toward $9.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PROF• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PROF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PROF)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PROF.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PROF)

✓Walkthrough of PROF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PROF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.45%📐 HORIZONTAL RANGE

2026-11-03O $5.86H $6.73L $5.86C $6.73VOL 475.5K

RES: $7.40SUP: $5.07SMA50: $6.20SMA200: $6.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PROF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PROF Butterfly Map → + Track PROF →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +65.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PROF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PROF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PROF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PROF)

Health Care Rank #463 of 1015 ⚔️ UTMD vs PROF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PROF vs. UTMD, OSUR, INFU, ANIK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Profound Medical Corp. (PROF) ranks #463 by composite RQD confidence (40/100, grade D-) and #550 by equity capitalization ($240.0M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with PROF at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PROF ACTIVE Profound Medical Corp.	D-	40/100	—	70.8%	-35.0%	+2.44%	$240.0M	Benchmark Subject
UTMD Utah Medical Products Inc.	C	62/100	—	57.1%	26.9%	+3.64%	$216.7M	/utmd-vs-prof →
OSUR OraSure Technologies Inc.	E	31/100	—	41.9%	-35.0%	-12.31%	$271.7M	/osur-vs-prof →
INFU InfuSystems Holdings Inc.	B+	77/100	43.4x	56.0%	12.8%	-1.63%	$280.2M	/infu-vs-prof →
ANIK Anika Therapeutics Inc.	D+	53/100	—	56.6%	-10.2%	-7.35%	$280.4M	/anik-vs-prof →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001628808 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Profound Medical Corp. (PROF) reported GAAP revenue of $16.1M (+65.3% vs. FY2024 revenue of $9.7M , and +172.9% cumulative change since FY2023) , GAAP net income of -$42.6M, operating cash flow of -$38.2M, and free cash flow of -$38.4M (-63.7% YoY). On the balance sheet, PROF closed FY2025 with $77.5M in total assets against $4.5M in total debt (Altman Z-Score: 5.97, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$16.1M	-$42.6M	-$38.2M	-$38.4M	$77.5M	$4.5M
FY2024 (FY)	2024-12-31	$9.7M	-$27.8M	-$23.5M	-$23.5M	$70.2M	$2.9M
FY2023 (FY)	2023-12-31	$5.9M	-$28.3M	-$22.6M	-$22.6M	—	—

3. PROF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PROF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PROF compare to UTMD and OSUR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PROF?

Where is PROF trading relative to its 50-day, 200-day, and 52-week technical levels?

PROF last traded at $6.73 (+2.44% on volume of 290,387 shares), positioning the stock +8.55% above its 50-day simple moving average ($6.20) and +1.20% above its 200-day simple moving average ($6.65). Across its 52-week range of $4.80 to $8.95, PROF sits at the 46.5% percentile with a 14-day RSI of 56.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($5.89 to $7.57).

Direct Sub-Reports: PROF RQD Cockpit PROF 12M Forecast PROF Earnings & Move PROF Dividends & DRIP PROF Insiders & 13F PROF Whale Options PROF Profit Sankey PROF News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

PROF — Profound Medical Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Profound Medical Corp. (PROF) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.73 (+2.44% 1D, market capitalization $240.0M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 70.8%, operating margin of -60.0%, and free cash flow yield of -17.93%.
Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.97, Piotroski F-Score of 5/9, and Debt/Equity of 0.07x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Profound Medical Corp. (PROF) is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry. Gross margin is reported at 70.8%, per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Profound Medical Corp. (PROF) reported $16.1M in annual revenue (up from $9.7M in FY2024, +65.3% YoY) and -$42.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.9M revenue, -$28.3M net income) through FY2025, PROF scaled operating cash flow to -$38.2M and free cash flow to -$38.4M, backed by $77.5M in total assets against $4.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.93% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $4.80 – $8.95 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only sector-level context is the Health Care sector and Medical/Dental Instruments industry classification from the profile. Investors should treat any ripple analysis beyond that classification as unsupported by the provided sources.

Key Question #1: Can PROF sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $16.1M and free cash flow of -$38.4M, how will capital allocation balance growth reinvestment against $4.5M in total debt?
Key Question #3: How sensitive is PROF's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PROF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Profound Medical Corp. (PROF) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PROF Debate Forum (3) ↓

🟢 CATALYST Seeking Alpha • 21h ago

Profound Medical: Q3 Revenue Beats Outlook (Rating Upgrade)

Seeking Alpha report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?

Yahoo Finance report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Profound Medical stock surges 20% on raised Q3 revenue outlook

Investing.com report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Profound Medical (PROF) Surges 17.1% Pre-Market Amid Broader Mar

GuruFocus report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Gross margin is expected to top 70% as Profound Medical (PROF) previews preliminary Q3 revenue.

Stock Titan report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade

Yahoo Finance report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 1d ago

What's going on in today's after hours session

ChartMill report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Raymond James reiterates Strong Buy on Profound Medical stock, $11 target

Investing.com report covering Profound Medical Corp. (PROF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PROF Bull vs. Bear Conversation Board — What's Your Call at $6.73?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PROF 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $8.02 (+22.1%)

📌 Pinned Debate

Revenue grew from $5.9M in FY 2023 to $16.1M in FY 2025 while the forensic balance sheet scored 14/20 with Debt/Equity of 0.07 and cash

Picked up a starter position in PROF in my $100K Virtual Cash book at $6.57. Revenue grew from $5.9M in FY 2023 to $16.1M in FY 2025 while the forensic balance sheet scored 14/20 with Debt/Equity of 0.07 and cash of $59.7M against debt of $4.5M.. Trading inside a $4.80–$8.95 52-week range with -17.93% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (70.8%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $5.39 (-18.0%)

Spot @ $6.57

Operating income fell to -$41.3M in FY 2025 with FCF of -$38.4M and FCF yield of -17.93%, while ROIC is -35% and insider conviction sco

Here is the bear case nobody on the bull side wants to address on PROF: Operating income fell to -$41.3M in FY 2025 with FCF of -$38.4M and FCF yield of -17.93%, while ROIC is -35% and insider conviction scores only 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.